Dems swayed by pharma lobbying push

Since the Democrats took over Congress, drugmakers have been scrambling to make nice with their former foes. They've been giving more money to more Democrats--more than they've donated to the blue side of the aisle, percentage-wise, since at least 1990. They've tied up traditionally Democratic lobbyists so that others on the opposite sides of their pet issues can't hire arm-twisting help from the same firms. They've sided with traditional adversaries to back expansion of the kids' health program--and by doing so have won brownie points to apply to other issues.

No wonder, then, that Democratic leaders haven't been able to pass either of their pet pharma industry measures: re-importing drugs from Canada and requiring pharma to negotiate prices with Medicare.

Indeed, as PhRMA President Billy Tauzin (photo) says, the Democratic takeover of Congress means "we just have more friends than we used to have. We're trying to find more." And a Republican senator who failed to beat the drug lobby on reimportation said, "They are an extremely powerful, effective lobby."

- read the article from the Washington Post

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.